Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 11,893 Shares

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 11,893 shares of Surrozen stock in a transaction dated Thursday, January 15th. The stock was bought at an average price of $19.89 per share, with a total value of $236,551.77. Following the acquisition, the director directly owned 1,005,732 shares of the company’s stock, valued at approximately $20,004,009.48. This trade represents a 1.20% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey acquired 18,052 shares of Surrozen stock. The shares were bought at an average price of $19.60 per share, for a total transaction of $353,819.20.
• On Friday, January 16th, Tim Kutzkey bought 2,562 shares of Surrozen stock. The stock was bought at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Wednesday, January 14th, Tim Kutzkey bought 5,523 shares of Surrozen stock. The shares were purchased at an average price of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The stock was purchased at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The stock was purchased at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The shares were purchased at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were purchased at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The stock was purchased at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

NASDAQ SRZN opened at $17.98 on Wednesday. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94. The stock’s 50 day moving average price is $18.98 and its two-hundred day moving average price is $14.13. The stock has a market capitalization of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, equities research analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current year.

Key Stories Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
• Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
• Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
• Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

Wall Street Analyst Weigh In

SRZN has been the subject of several analyst reports. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a research report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Institutional Trading of Surrozen

A number of hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC boosted its stake in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the period. Geode Capital Management LLC lifted its holdings in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Armistice Capital LLC bought a new position in Surrozen during the second quarter worth $536,000. Woodline Partners LP acquired a new position in shares of Surrozen in the third quarter valued at $621,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Surrozen in the third quarter valued at about $889,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.